¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"rebound hypertension"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® rebound phenomenon ÇÑ±Û ¹Ý¹ßÇö»ó, ¹Ýµ¿Çö»ó
¼³¸í   
  ¼Ò³ú ±â´ÉÀå¾Ö¿¡¼­ »çÁöÀÇ ´ëÇ×±ÙÀ° »çÀÌÀÇ ÇùÁ¶¼º »ó½ÇÀǠ¡Èķμ­, È¯ÀÚ¿¡°Ô ¾çÆÈÀ» ¼öÆòÀ¸·Î »¸°Ô ÇÏ°í ±× ÆÈÀ» °­ÇϰԠġ¸é Á¤»óÀΠ°æ¿ì´Â °ð ¿ø»óÀ¸·Î ¿Ã¸®´Âµ¥ ºñÇÏ¿© È¯ÀÚ¿¡ À־´Â ¿øÀ§Ä¡·Î µ¹¾Æ¿À´Â µ¥ ¸î ¹øÀ̳ª ¶³°Ô µÈ´Ù.
¿µ¹® hypertension ÇÑ±Û °íÇ÷¾Ð
¼³¸í   
  µ¿¸ÆÀÇ Ç÷¾ÐÀÌ ³ôÀº °Í. ÀϹÝÀûÀ¸·Î ¸»Çϴ °íÇ÷¾ÐÀº ÀÌ µ¿¸Æ¼º °íÇ÷¾ÐÀ» ¸»ÇÑ´Ù. Ç÷¾ÐÀ̶õ Ç÷°ü¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϴ °ÍÀ¸·Î ´ë°³ Æ¯ÀÌÇÑ ¼³¸íÀÌ ¾øÀ¸¸é µ¿¸ÆÀÇ ¾Ð·ÂÀ» ¸»ÇÑ´Ù. Ç÷¾Ð¿¡´Â ¼öÃà±âÇ÷¾Ð°ú À̿ϱâÇ÷¾ÐÀÌ ÀÖ´Ù. ¼öÃà±âÇ÷¾ÐÀ̶õ ½ÉÀåÀÌ ¼öÃàÇÒ ¶§ÀÇ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϰí À̿ϱâ Ç÷¾ÐÀ̶õ ½ÉÀåÀÌ ÀÌ¿ÏÇÒ °æ¿ì¿¡ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÑ´Ù. ´ç¿¬È÷ ¼öÃà±â Ç÷¾ÐÀÌ À̿ϱâ Ç÷¾Ðº¸´Ù ³ô´Ù. Ç÷¾ÐÀ» ¸»ÇÒ ¶§¿¡ 120/80À̶ó°í Àû´Â °ÍÀÇ ¾ÕÀÇ °ÍÀº ¼öÃà±â Ç÷¾ÐÀ» ÀǹÌÇÏ°í µÚ¿¡ Àû´Â 80Àº À̿ϱâ Ç÷¾ÐÀ» ÀǹÌÇÑ´Ù.
  
  °íÇ÷¾ÐÀº ÁַΠÀ̿ϱâÀÇ Ç÷¾ÐÀ» ±âÁØÀ¸·Î Á¤ÇÑ´Ù. ¿©·¯ °¡Áö ±âÁØÀÌ ÀÖÀ¸³ª À̿ϱâ Ç÷¾ÐÀÌ 90mmHgÀÌ»óÀΠ°æ¿ì¸¦ ¸»ÇÑ´Ù. °íÇ÷¾Ð ÀÚü¿¡ ÀÇÇÑ Áõ»óÀº º°·Î ¾ø´Ù. ´Ù¸¸ °íÇ÷¾Ð¿¡ ÀÇÇÑ ÇÕº´Áõ°ú µ¿¸Æ°æÈ­ÀÇ ÃËÁø¿¡ ÀÇÇØ º´¹ßÇϴ Áúȯ¿¡ ÀÇÇÏ¿© Áõ»óÀÌ »ý±ä´Ù. °íÇ÷¾Ð¿¡ ÀÇÇÑ ÇÕº´ÁõÀº ´ë°³ Ç÷°ü¿¡ °É¸®´Â °úµµÇÑ ¾Ð·ÂÀ¸·Î ÀÎÇÑ Ç÷°üÀÇ ¼Õ»óÀÌ Áß¿äÇÑ ¿øÀÎÀÌ´Ù.
  
  °íÇ÷¾ÐÀº µ¿¸Æ°æÈ­ÀÇ ÁÖ¿ä À¯¹ßÀÎÀÚ ÁßÀÇ ÇϳªÀÌ´Ù. µ¿¸Æ°æÈ­´Â µ¿¸ÆÀÇ º®ÀÌ µÎÅÍ¿öÁö°í µ¿¸ÆÀ̠ź·ÂÀ» ÀÒ¾î¹ö¸®´Â ÁúȯÀÌ´Ù. ¾î¶² µ¿¸ÆÀÌ µ¿¸Æ°æÈ­¿¡ °É¸®¸é ÀÌ µ¿¸ÆÀº µÎÅÍ¿öÁø Ç÷°üº®¿¡ ÀÇÇØ¼­ ³»°æÀÌ ÀÛ¾ÆÁö°Ô µÈ´Ù. ÀÌ·¸°Ô µÇ¸é ±× µ¿¸ÆÀ¸·ÎºÎÅÍ Ç÷¾×À» °ø±Þ¹Þ´ø Àå±â´Â Ç÷¾×À» Àû°Ô °ø±Þ¹Þ°Ô µÇ°í ±× Á¤µµ°¡ ½ÉÇϰԠµÇ¸é ±× Àå±â´Â °á±¹ ¼Õ»óÀ» ÀÔ°Ô µÈ´Ù. µ¿¸Æ°æÈ­·Î ÀÎÇÑ Áúº´ÀÇ ´ëÇ¥ÀûÀΠ¿¹´Â ½ÉÀåÀÇ ±ÙÀ°¿¡ Ç÷¾×À» °ø±ÞÇϴ ½ÉÀ嵿¸Æ¿¡ µ¿¸Æ°æÈ­ÀÇ º¯È­°¡ ¿À´Â ½ÉÀ嵿¸Æº´ÀÌ´Ù.
  
  °íÇ÷¾ÐÀÇ Ä¡·á¿¡ ¾²À̴ ¾à¹°Àº ´ÙÀ½°ú °°Àº °ÍÀÌ ÀÖ´Ù.
  
  -ÀÌ´¢Á¦-ÄáÆÏ¿¡¼­ ¼öºÐ°ú ÀüÇØÁúÀÇ ¹èÃâÀ» ÃËÁø½Ã۴ ¾à¹°. Ã¼³»ÀÇ ¼öºÐÀÇ ¾çÀ» °¨¼Ò½ÃÄѼ­ Ç÷¾×ÀÇ È帣´Â ¾çÀ» Àû°ÔÇÏ°í ¶Ç Ç÷°üÁÖÀ§ Á¶Á÷ÀÇ ¼öºÐÀÇ °¨¼Ò·Î Ç÷°üÀ» È®Àå½Ã۴ ¿ªÇÒ(Ç÷°üÀÌ ÀÖ°í ±× Ç÷°üÀ» ½×°í Àִ Á¶Á÷¿¡ ¼öºÐÀÌ Â÷ ÀÖÀ¸¸é ±× Á¶Á÷ÀÌ Ç÷°üÀ» ´­·¯¼­ Ç÷°üÀÌ È®ÀåÇϴ °ÍÀ» ¹æÇØÇÑ´Ù)·Î Ç÷¾ÐÀ» °¨¼Ò½ÃŲ´Ù.
  
  -Ä®½·-Åë·ÎÂ÷´ÜÁ¦£­¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡´Â Ä®½·ÀÌ ÇÊ¿äÇÏ´Ù. Áï Ç÷°üÀÇ ¼öÃà¿¡ °ü¿©Çϴ Ç÷°üµµ ¿ª½Ã ¼öÃàÀ» À§Çؼ­´Â Ä®½·ÀÌ ÇÊ¿äÇÏ´Ù. Ä®½·-Åë·ÎÂ÷´ÜÁ¦´Â ±ÙÀ°¼¼Æ÷ ¼ÓÀ¸·Î Ä®½·ÀÌ µé¾î°¡´Â °ÍÀ» ¹æÁöÇØ¼­ Ç÷°ü±ÙÀ°ÀÇ ¼öÃàÀ» ¹æÇØÇϰí À̷ΠÀÎÇØ¼­ Ç÷°üÀÇ È®ÀåÀ» À¯µµÇÑ´Ù.
  
  -¾ËÆÄÂ÷´ÜÁ¦, º£Å¸Â÷´ÜÁ¦-Ç÷°üÀº ÀÚÀ²½Å°æ°èÀÇ Áö¹è¸¦ ¹Þ´Â´Ù. ±×Áß¿¡¼­µµ Ç÷°üÀº ±³°¨½Å°æÀÇ ¿µÇâ¿¡ ÀÇÇØ¼­ ¼öÃà°ú ÀÌ¿ÏÀ» ÇÑ´Ù. ±³°¨½Å°æÀÇ ÀÛ¿ëÀº ±× ¼ö¿ëü¿¡ µû¶ó ´Þ¶óÁø´Ù. ±³°¨½Å°æÀÇ ¼ö¿ëüÀÇ Á¾·ù¿¡´Â ¾ËÆÄ¼ö¿ëü¿Í º£Å¸¼ö¿ëü°¡ ÀÖ´Ù. Ç÷°üÀ» Áö¹èÇϰí Àִ ±³°¨½Å°æ¿¡¼­ ¾ËÆÄ¼ö¿ëü´Â Ç÷°üÀÇ ¼öÃàÀ» ÀÏÀ¸Å°°í º£Å¸¼ö¿ëü´Â Ç÷°üÀÇ È®ÀåÀ» ÀÏÀ¸Å²´Ù. ±×·¯¹Ç·Î ¾ËÆÄ¼ö¿ëüÀÇ ÀÛ¿ëÀ» ¸·´Â °æ¿ì¿¡ Ç÷°üÀÇ È®ÀåÀ» À¯µµÇÒ ¼ö ÀÖ°í º£Å¸-¼ö¿ëüÀÇ ÀÛ¿ëÀ» Ç×Áø½Ãų °æ¿ì¿¡ ¿ª½Ã Ç÷°üÀÇ È®Á¤À» À¯µµÇÒ ¼ö ÀÖ´Ù.
¿µ¹® renal hypertension ÇÑ±Û ÄáÆÏ¼º°íÇ÷¾Ð
¼³¸í   
  ÄáÆÏ½ÇÁúÀÇ º´º¯À¸·Î ÀÎÇØ ¾ß±âµÈ °íÇ÷¾Ð. ÄáÆÏÀÇ ´ëÇ¥Àû ±â´ÉÀº ³ëÆó¹° ¹× ¼öºÐÀÇ ¹è¼³ÀÌ´Ù. ±×·±µ¥ ÀÌ·¯ÇÑ ÄáÆÏ±â´É¿¡ ÀÌ»óÀÌ »ý°åÀ» °æ¿ì Ã¼³»¿¡ °úÀ×¼öºÐÀÇ ÃàÀûÀÌ ¹ß»ýÇϰԠµÈ´Ù. À̿Ͱ°Àº °úÀ×¼öºÐÀÇ ÃàÀûÀº Ç÷°ü³» Á¤¼ö¾ÐÀ» »ó½Â½ÃÄÑ °íÇ÷¾ÐÀ» À¯¹ßÇϰԠµÈ´Ù. Ä¡·á´Â ¿øÀΠÄáÆÏº´ÀÇ ±³Á¤À̸ç ÀÌÀ¯¸¦ ¸ð¸£´Â ¿ø¹ß°íÇ÷¾Ð°ú ´Þ¸® ÄáÆÏ¼º°íÇ÷¾ÐÀÇ °æ¿ì¿¡´Â ¿øÀΠÄáÆÏº´ÀÌ ±³Á¤µÇ¸é °íÇ÷¾Ðµµ »ç¶óÁö°Ô µÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rebound
    1. ¹Ýµ¿- 2. ¹Ýµ¿
  • rebound hyperglycemia
    ¹Ýµ¿°íÇ÷´ç(Áõ)
  • rebound nystagmus
    ¹Ýµ¿´«¶³¸², ¹Ýµ¿¾ÈÁø
  • rebound phenomenon
    ¹Ýµ¿Çö»ó
  • rebound tenderness
    ¹Ýµ¿¾ÐÅë, µÇƦÅëÁõ
  • accelerated hypertension
    °¡¼Ó°íÇ÷¾Ð
  • adrenal hypertension
    ºÎ½Å¼º°íÇ÷¾Ð
  • borderline hypertension
    °æ°è°íÇ÷¾Ð
  • diastolic hypertension
    È®Àå±â°íÇ÷¾Ð
  • essential hypertension
    º»Å°íÇ÷¾Ð
  • hypertension
    1. °íÇ÷¾Ð 2. °íÇ÷¾ÐÁõ 3. °í¾Ð
  • intracranial hypertension
    µÎ°³³»¾Ð»ó½Â
  • juvenile hypertension
    ¼Ò¾Æ°íÇ÷¾Ð
  • labile hypertension
    ºÒ¾ÈÁ¤°íÇ÷¾Ð
  • low renin hypertension
    Àú·¹´Ñ°íÇ÷¾Ð
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rebound phenomenon
    ¹Ýµ¿Çö»ó
  • rebound
    ¹Ýµ¿, ¹Ýµ¿-
  • rebound tenderness
    ¹Ýµ¿¾ÐÅë, µÇƦÅëÁõ
  • hypertension
    °íÇ÷¾Ð
  • ocular hypertension
    °í¾È¾ÐÁõ
  • portal hypertension
    ¹®¸Æ°íÇ÷¾Ð
  • pregnancy-induced hypertension
    ÀӽŰíÇ÷¾Ð
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð, ÇãÆÄ°íÇ÷¾Ð
  • renovascular hypertension
    ÄáÆÏÇ÷°ü°íÇ÷¾Ð, ½ÅÀåÇ÷°ü°íÇ÷¾Ð
  • sinusoidal hypertension
    ±¼Ç÷°ü°íÇ÷¾Ð
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rebound hypertension
    ¹Ýµ¿°íÇ÷¾Ð
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rebound hyperglycemia
    ¹Ýµ¿°íÇ÷´çÁõ
  • rebound nystagmus
    ¹Ýµ¿´«¶³¸²
  • rebound phenomenon
    ¹Ý¹ßÇö»ó, ¹Ýµ¿Çö»ó
  • rebound
    ¹Ýµ¿¼º, ¹Ý¹ß, ¹Ýµ¿
  • rebound tenderness
    ¹Ýµ¿¾ÐÅë, µÇƦÅëÁõ
  • accelerated hypertension
    °¡¼Ó°íÇ÷¾Ð
  • adrenal hypertension
    ºÎ½Å°íÇ÷¾Ð
  • borderline hypertension
    °æ°è°íÇ÷¾Ð
  • diastolic hypertension
    È®Àå±â°íÇ÷¾Ð
  • essential hypertension
    º»Å°íÇ÷¾Ð
  • hypertension
    °íÇ÷¾Ð
  • intracranial hypertension
    µÎ°³³»¾Ð»ó½Â
  • juvenile hypertension
    ¼Ò¾Æ°íÇ÷¾Ð
  • labile hypertension
    (¢¡borderline hypertension) °æ°è°íÇ÷¾Ð
  • low renin hypertension
    Àú·¹´Ñ°íÇ÷¾Ð
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • indirect tenderness =rebound t.
    °£Á¢¾Ð Åë(¡­äâ÷Ô).
  • indirect tenderness =rebound t.
    °£Á¢¾ÐÅë(¡­¾ÐÅë).
  • Goldblatt hypertension
    Goldblatt °íÇ÷¾Ð(ÍÔúìäâ)
  • Hypertension
    °íÇ÷¾Ð(ÍÔúìäâ)
  • accelerated hypertension
    °¡¼Ó¼º °íÇ÷¾Ð.
  • adrenal hypertension
    ºÎ½Å¼º °íÇ÷¾ÐÁõ(¡­ÍÔúìäâñø).
  • arterial hypertension
    µ¿¸Æ(¼º) °íÇ÷¾Ð(Áõ).
  • hypertension
    °íÇ÷¾Ð(Áõ)(ÍÔúìäâñø), ±äÀåÇ×Áø(Áõ)(ÑÌíåùñòäñø).
  • hypertension
    °íÇ÷¾Ð(Áõ)(ÍÔúìäâ)
  • hypertension cranienne ºÒ
    ³ú¾ÐÇ×Áø(Áõ).
  • hypertension paroxystique ºÒ
    ¹ßÀÛ¼º °íÇ÷¾Ð(Áõ)(Û¡íÂàõÍÔúìäâñø).
  • hypertension,benign nephrosclerosis
    ¾ç¼º ½Å°æÈ­Áõ
  • hypertension,essential
    º»Å¼º(Üâ÷¾àõ)
  • hypertension,malignant
    ¾Ç¼º(äÂàõ)
  • hypertension,portal
    ¹®¸Æ¼º(Ú¦Øæàõ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rebound hypertension
    ¹Ýµ¿¼º °íÇ÷¾Ð.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • indirect tenderness =rebound t.
    °£Á¢¾ÐÅë(¡­¾ÐÅë).
  • indirect tenderness =rebound t.
    °£Á¢¾Ð Åë(¡­äâ÷Ô).
  • rebound
    ¹Ýµ¿(ÚãÔÑ)
  • rebound hyperglycemia
    ¹Ýµ¿°íÇ÷´ç.
  • rebound nystagmus
    ¹Ýµ¿¾ÈÁø
  • rebound tenderness
    ¹Ýµ¿¾ÐÅë.
  • steroid rebound phenomenon
    ½ºÅ×·ÎÀÌµå ¹ÝµµÇö»ó(¡­ÚãÔ¯úÞßÚ).
  • accelerated hypertension
    °¡¼Ó¼º °íÇ÷¾Ð.
  • adrenal hypertension
    ºÎ½Å¼º °íÇ÷¾ÐÁõ(¡­ÍÔúìäâñø).
  • arterial hypertension
    µ¿¸Æ(¼º) °íÇ÷¾Ð(Áõ).
  • borderline hypertension
    °æ°è¿ª°íÇ÷¾Ð.
  • borderline hypertension
    °æ°è¿ª °íÇ÷¾Ð(ÌÑÍ£æ´ ÍÔúìäâ).
  • diastolic hypertension
    È®Àå±â°íÇ÷¾Ð(¡­ÍÔúìäâ).
  • essential hypertension
    º»Å¼º °íÇ÷¾Ð.
  • essential hypertension
    º»Å¼º(Üâ÷¾àõ)°íÇ÷¾Ð(ÍÔúìäâ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • renal hypertension
    ½Å°íÇ÷¾Ð(ãìÍÔúìäâ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rebound
    ¹Ýµ¿¼º, ¹Ýµ¿Çö»ó
  • rebound phenomenon
    ¹Ýµ¿Çö»ó
  • essential hypertension
    º»Å¼º°íÇ÷¾Ð
  • hypertension
    °íÇ÷¾ÐÁõ, ±äÀåÇ×ÁøÁõ
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾ÐÁõ
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ, ¹®¸Æ°íÇ÷¾Ð
  • primary hypertension
    ¿ø¹ß(¼º)°íÇ÷¾ÐÁõ
  • renal hypertension
    ½Å¼º°íÇ÷¾Ð
  • renovascular hypertension
    ½ÅÇ÷°ü¼º°íÇ÷¾Ð
  • splenoportal hypertension
    ºñ¹®¸Æ¼º°íÇ÷¾ÐÁõ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RT Rebound Tenderness
T/RT Tenderness/Rebound Tenderness
PIR postinhibition rebound; protein identification resource
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
IPH idiopathic portal hypertension; idiopathic pulmonary hemosiderosis; idiopathic pulmonary hypertensio...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PIR Postinhibitory rebound
STOP Hypertension Swedish Trial in Old Patients with Hypertension
ARH Adrenal regeneration hypertension
AH Arterial Hypertension
AHT Arterial Hypertension
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • rebound
    ¹Ýµ¿¼º
    ÀÚ±ØÀÇ Á¦°Å ½Ã¿¡ º¼¼ö ÀÖ´Â ¿ª¹æÇâÀÇ ¹ÝÀÀ.
  • rebound phenomenon
    ¹Ýµ¿ Çö»ó
    ¼Ò³ú ±â´É Àå¾Ö¿¡¼­ »çÁöÀÇ ±æÇ×±Ù »çÀÌÀÇ ÇùÁ¶¼º »ó½ÇÀÇ Â¡Èķμ­, ȯÀÚ¿¡°Ô ¾çÆÈÀ» ¼öÆòÀ¸·Î »¸°Ô ÇÏ°í ±× ÆÈÀ» °­ÇÏ°Ô Ä¡¸é Á¤»óÀÎ °æ¿ì´Â °ð ¿ø»óÀ¸·Î ¿Ã¸®´Â µ¥ ºñÇÏ¿© ȯÀÚ¿¡ À־´Â ¿øÀ§Ä¡·Î µ¹¾Æ¿À´Â µ¥ ¸î ¹øÀ̳ª ¶³°Ô µÈ´Ù.
  • rebound tenderness
    ¹Ýµ¿¼º ¾ÐÅë, ¹Ýµ¿ ¾ÐÅë
    ´©¸£´Â ÈûÀ» Á¦°ÅÇÒ ¶§¿¡ ´À³¢´Â µ¿Åë.
  • steroid rebound phenomenon
    ½ºÅ×·ÎÀÌµå ¹Ýµµ Çö»ó
  • accelerated hypertension
    °¡¼Ó¼º °íÇ÷¾Ð
  • essential hypertension
    º»Å¼º °íÇ÷¾Ð
    1. Ưº°ÇÑ ¿øÀÎÀÌ ¾Ë·ÁÁöÁö ¾ÊÀº °íÇ÷¾ÐÀ» ÀǹÌÇϸç ÀÌ´Â Àüü °íÇ÷¾Ð ȯÀÚÀÇ 85-90£¥¸¦ Â÷ÁöÇÑ´Ù. 2. À¯Àü, Á¤½ÅÀû ½ºÆ®·¹½º, ¿°ºÐÀÇ Áõ°¡ µî Ç÷¾Ð »ó½ÂÀÌ º¹ÇÕÀûÀÎ ¿øÀÎ ÇüÅ·Π³ªÅ¸³­´Ù.
  • hypertension paroxystique
    ºÒ ¹ßÀÛ¼º °íÇ÷¾Ð
  • juvenile hypertension
    ¿¬¼Ò¼º °íÇ÷¾ÐÁõ, ¿¬¼Ò¼º °íÇ÷¾Ð
  • labile hypertension
    ºÒ¾ÈÁ¤¼º °íÇ÷¾Ð
  • nephrogenous hypertension
    ½Å¼º °íÇ÷¾Ð
  • ocular hypertension indicator
    ¾È±¸ °íÇ÷¾Ð ÁöÇ¥
  • orthostatic hypertension
    ±â¸³¼º °íÇ÷¾Ð, ÀÚ¼¼¼º °íÇ÷¾Ð
  • portal hypertension
    ¹®¸Æ¼º °íÇ÷¾Ð, °£¹®¸Æ °íÇ÷¾Ð, ¹®¸Æ¾Ð Ç×ÁøÁõ, ¹®¸Æ °íÇ÷¾Ð
  • primary hypertension
    ¿ø¹ß °íÇ÷¾ÐÁõ, ¿ø¹ß¼º °íÇ÷¾ÐÁõ
  • pulmonary arterial hypertension
    Æó ¼øÈ¯ ½Â¾Ð
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
rebound Just like a rebound in basketball when the ball reverses its course and bounces back off the backboard, in medicine a rebound is a reversal of response upon withdrawal of the stimulus.
(12 Dec 1998)
rebound effect The characteristic of a drug to produce reverse effects when either the effect of the drug has passed or when the patient no longer responds to the drug.
(18 Nov 1997)
rebound phenomenon Generally, any phenomenon in which a variable that has been displaced from its normal state by a disturbing influence temporarily deviates from normal in the opposite direction when the disturbing influence is suddenly removed, before finally stabilizing at its normal state, i.e., a phenomenon involving undershoot; e.g., the subsequent hypoglycaemia that may follow injection of glucose, because the initial hyperglycaemia caused excessive secretion of insulin.
Synonym: Stewart-Holmes sign
(05 Mar 2000)
accelerated hypertension <cardiology> A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure.
Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension.
(27 Sep 1997)
adrenal hypertension Hypertension due to an adrenal medullary pheochromocytoma or to hyperactivity or functioning tumour of the adrenal cortex.
(05 Mar 2000)
benign hypertension Hypertension that runs a relatively long and symptomless course.
(05 Mar 2000)
borderline hypertension By consensus, that blood pressure zone between highest acceptable "normal" blood pressure and hypertensive blood pressure. The Framingham Heart Study defines this as pressures between 140 and 160 mm Hg systolic and 90 and 95 mm Hg diastolic.
(05 Mar 2000)
pale hypertension Hypertension with pallor of the skin, a severe form with pronounced constriction of peripheral vessels.
(05 Mar 2000)
malignant hypertension A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure.
Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension.
(27 Sep 1997)
renal hypertension Hypertension secondary to renal disease.
(05 Mar 2000)
renovascular hypertension Hypertension produced by renal arterial obstruction.
(05 Mar 2000)
Goldblatt hypertension Increased blood pressure following obstruction of blood flow to one kidney.
Synonym: Goldblatt phenomenon.
(05 Mar 2000)
portal hypertension Any increase in the portal vein (in the liver) pressure due to anatomic or functional obstruction (for example alcoholic cirrhosis) to blood flow in the portal venous system. Indicators of portal hypertension are: oesophageal varices, haemorrhoids, enlarged veins on the anterior abdominal wall (caput Medusae) and ascites (fluid within the abdominal cavity).
(27 Sep 1997)
portal hypertension: classification <radiology> Presinusoidal, extrahepatic: portal vein obstruction (extrinsic compression, phlebitis, OC, coagulopathy, tumour invasion, pancreatitis, neonatal omphalitis), dynamic: traumatic/neoplastic arterioportal fistula, segmental portal hypertension: splenic/superior mesenteric vein occlusion, intrahepatic (obstruction of portal venules): congenital hepatic fibrosis, primary biliary cirrhosis, sarcoid, myelofibrosis, schistosomiasis, idiopathic noncirrhotic fibrosis, Wilson disease, reticuloendotheliosis, Felty syndrome, chronic malaria, toxic fibrosis (arsenic, copper, PVC vapors) sinusoidal, cirrhosis, sclerosing cholangitis postsinusoidal, Budd-Chiari syndrome, constrictive pericarditis, congestive heart failure
(12 Dec 1998)
postcapillary pulmonary hypertension <radiology> Heart: LV failure, mitral stenosis, LA myxoma / thrombus, cor triatriatum, Pulmonary veins: congenital stenosis of pulmonary vein origin, mediastinal granulomata and neoplasms, idiopathic pulmonary veno-occlusive disease, anomalous pulmonary venous return
(12 Dec 1998)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
rebound hypertension An increase in blood pressure that follows withdrawal from an antihypertensive drug.
Ãâó:
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hypertension
    °íÇ÷¾Ð; °úµµ ±äÀå
  • hypertension
    °íÇ÷¾Ð
  • rebound
    µÇÆ¢´Ù
  • rebound
    (°ø µîÀÌ)µÇ Æ¢´Ù;(ÇàÀ§°¡)(Àڱ⿡°Ô·Î)µÇµ¹¾Æ¿À´Ù;(ÁÂÀý.½ÇÆÐ µî¿¡¼­)´Ù½Ã ÀϾ´Ù;¹ÝÇâÇÏ´Ù;µÇÆ¢°ÔÇÏ´Ù;µ¹ÀÌŰ´Ù;¹ÝÇâ½ÃŰ´Ù;µÇƦ;¹ÝÇâ;¹Ý¹ß;»ê¿ï¸²(echo);¹Ýµ¿(°¨Á¤µîÀÇ);¸®¹Ù¿îµå(º¼)
  • rebound
    REBINDÀÇ °ú°Å.°ú°ÅºÐ»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á